Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT)
Resumen:
Coagulopathy and thrombosis associated with coronavirus disease 2019 (COVID-19) represent a major issue in the management of this disease. In the past months, clinical studies have demonstrated that COVID-19 patients present with a particular hypercoagulable state, in which a markedly increased D-dimer concomitant with increased levels of fibrinogen are observed. This hypercoagulable state leads to an increased risk of thrombosis, which seems to be higher among those patients with critical symptoms of COVID-19. The best therapeutic approach to prevent thrombotic events in COVID-19 has not been determined yet and several questions regarding thromboprophylaxis therapy, such as the time to initiate anticoagulation, type of anticoagulant and dose regimen, have emerged among physicians. To address these concerns, several medical societies have published position papers to provide the opinion of thrombosis experts on the management of coagulopathy and thrombosis associated with COVID-19. In line with this, the Latin America Cooperative Group of Hemostasis and Thrombosis (Grupo CLAHT) has constituted a panel of experts in thrombosis and hemostasis to discuss the available data on this topic. The aim of this review is to summarize the current evidence regarding hemostatic impairment and thrombotic risk in COVID-19 and to provide a carefully revised opinion of Latin American experts on the thromboprophylaxis and management of thrombotic events and coagulopathy in patients with suspected COVID-19.
| 2021 | |
|
COVID-19 Tromboprofilaxia Trombosis Tromboembolia SARS-CoV-2 Neumonía ANTICOAGULANTES USOS TERAPÉUTICOS CONSENSO HUMANOS PREVENCIÓN DE ENFERMEDADES TROMBOEMBOLIA VENOSA TERAPÉUTICA |
|
| Inglés | |
| Universidad de la República | |
| COLIBRI | |
| https://hdl.handle.net/20.500.12008/55391 | |
| Acceso abierto | |
| Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0) |
| _version_ | 1877555259029585920 |
|---|---|
| author | Guillermo Espósito, Cecilia |
| author2 | Casais, Patricia Cesarman-Maus, Gabriela Andrade-Orsi, Fernanda Martínez-Rovira, Raúl de-Campos-Guerra, Joao C. Rezende, Suely M. Izaguirre-Ávila, Raúl |
| author2_role | author author author author author author author |
| author_facet | Guillermo Espósito, Cecilia Casais, Patricia Cesarman-Maus, Gabriela Andrade-Orsi, Fernanda Martínez-Rovira, Raúl de-Campos-Guerra, Joao C. Rezende, Suely M. Izaguirre-Ávila, Raúl |
| author_role | author |
| bitstream.checksum.fl_str_mv | 6429389a7df7277b72b7924fdc7d47a9 a006180e3f5b2ad0b88185d14284c0e0 00c6a163e62314ee9d2a181a90bf9e84 d62648cf14c1e37917d392ac87012955 b5dcdb3550e165da4b424d36d0dc0a84 |
| bitstream.checksumAlgorithm.fl_str_mv | MD5 MD5 MD5 MD5 MD5 |
| bitstream.url.fl_str_mv | http://localhost:8080/xmlui/bitstream/20.500.12008/55391/5/license.txt http://localhost:8080/xmlui/bitstream/20.500.12008/55391/2/license_url http://localhost:8080/xmlui/bitstream/20.500.12008/55391/3/license_text http://localhost:8080/xmlui/bitstream/20.500.12008/55391/4/license_rdf http://localhost:8080/xmlui/bitstream/20.500.12008/55391/1/Guidelines+for+prophylaxis+and+anti+thrombotic+treatment.pdf |
| collection | COLIBRI |
| dc.contributor.filiacion.none.fl_str_mv | Guillermo Espósito Cecilia, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de Clínicas. Cátedra de Hematología Casais Patricia, Universidad de Buenos Aires (Argentina). Instituto de Investigaciones en Salud Pública. Departamento de Epidemiología Clínica y Evidencia Cesarman-Maus Gabriela, Instituto Nacional de Cancerología (México). Departamento de Hematología Andrade-Orsi Fernanda, Universidades Estadual de Campinas (Brasil). Faculdade de Ciências Médicas. Departamento de Patologia Martínez-Rovira Raúl, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de Clínicas. Unidad de Hemostasis y Trombosis de-Campos-Guerra Joao C., Centro de Hematologia de São Paulo (Brasil). Hospital Israelita Albert Einstein Rezende Suely M., Universidade Federal de Minas Gerais (Brasil). Faculdade de Medicina Izaguirre-Ávila Raúl, Instituto Nacional de Cardiología Ignacio Chávez (México). Departamento de Hematología |
| dc.coverage.spatial.es.fl_str_mv | AMÉRICA LATINA |
| dc.creator.none.fl_str_mv | Guillermo Espósito, Cecilia Casais, Patricia Cesarman-Maus, Gabriela Andrade-Orsi, Fernanda Martínez-Rovira, Raúl de-Campos-Guerra, Joao C. Rezende, Suely M. Izaguirre-Ávila, Raúl |
| dc.date.accessioned.none.fl_str_mv | 2026-06-05T14:25:33Z |
| dc.date.available.none.fl_str_mv | 2026-06-05T14:25:33Z |
| dc.date.issued.none.fl_str_mv | 2021 |
| dc.description.abstract.none.fl_txt_mv | Coagulopathy and thrombosis associated with coronavirus disease 2019 (COVID-19) represent a major issue in the management of this disease. In the past months, clinical studies have demonstrated that COVID-19 patients present with a particular hypercoagulable state, in which a markedly increased D-dimer concomitant with increased levels of fibrinogen are observed. This hypercoagulable state leads to an increased risk of thrombosis, which seems to be higher among those patients with critical symptoms of COVID-19. The best therapeutic approach to prevent thrombotic events in COVID-19 has not been determined yet and several questions regarding thromboprophylaxis therapy, such as the time to initiate anticoagulation, type of anticoagulant and dose regimen, have emerged among physicians. To address these concerns, several medical societies have published position papers to provide the opinion of thrombosis experts on the management of coagulopathy and thrombosis associated with COVID-19. In line with this, the Latin America Cooperative Group of Hemostasis and Thrombosis (Grupo CLAHT) has constituted a panel of experts in thrombosis and hemostasis to discuss the available data on this topic. The aim of this review is to summarize the current evidence regarding hemostatic impairment and thrombotic risk in COVID-19 and to provide a carefully revised opinion of Latin American experts on the thromboprophylaxis and management of thrombotic events and coagulopathy in patients with suspected COVID-19. |
| dc.description.es.fl_txt_mv | Cecilia Guillermo-Esposito 1, Patricia Casais 2, Gabriela Cesarman-Maus 3, Fernanda Andrade-Orsi 4, Rosario Martínez-Rovira 5, Joao C de-Campos-Guerra 6, Suely M Rezende 7, Raúl Izaguirre-Ávila 8, Raúl Altman 9, José Ceresetto 9, Cecilia Colorio 9, Cristina Duboscq 9, Claudio Martín Rosa 9, Soledad Molnar 9, Diana García 9, Mario Luis Tejarina 10, Nelson Nina García 10, Juan Choque Pacheco 10, Chiara Chindamo J. María 11, Gloria Ramos Ramos 12, Guillermo León Basantes 12, Aura Milena Reyna 12, Miriam Cantero Guevara 12, Mateo Porres Aguilar 13, Luis Meillón 13, Flavio Adrián Grimaldo 13, Ludwing Alexander Bacon Fonseca 14, Al Ávila Milord 15, Ricardo Aguilar 15, Rafael Aparicio 15, Paula de Guggiari 16, Gloria Chumpitaz 17, Pedro Pablo García 17, Blanca Steffano 18, Sandra Damiano 18, Juan Serrano 19, Marisol Zavahra 19 Affiliations 1Cátedra de Hematología, Facultad de Medicina, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay. 2Departamento de Epidemiología Clínica y Evidencia, Instituto de Investigaciones en Salud Pública, Universidad de Buenos Aires, Argentina. 3Departamento de Hematología, Instituto Nacional de Cancerología, Ciudad de México, México. 4Departamento de Patología Clínica, Escuela de Ciencias Médicas, Universidad de Campinas, Campinas-Sao Paulo, Brasil. 5Unidad de Hemostasis y Trombosis, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay. 6Hospital Israelita Albert Einstein, Centro de Hematología de Sao Paulo, Sao Paulo, Brasil. 7Facultad de Medicina, Universidad Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brasil. 8Departamento de Hematología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México. 9Argentina 10Bolivia 11Brasil 12Colombia 13México 14Nicaragua 15Panamá 16Paraguay 17Perú 18Uruguay 19Venezuela |
| dc.format.extent.es.fl_str_mv | 8 p. |
| dc.format.mimetype.es.fl_str_mv | application/pdf |
| dc.identifier.citation.es.fl_str_mv | Guillermo Espósito C, Casais P, Cesarman-Maus G y otros. Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT). Archivos de cardiología de México [en línea]. 2021;91:47-54 |
| dc.identifier.doi.none.fl_str_mv | 10.24875/ACM.20000291 |
| dc.identifier.eissn.none.fl_str_mv | 1665-1731 |
| dc.identifier.uri.none.fl_str_mv | https://hdl.handle.net/20.500.12008/55391 |
| dc.language.iso.none.fl_str_mv | en eng |
| dc.publisher.es.fl_str_mv | Instituto Nacional de Cardiología Ignacio Chávez |
| dc.relation.none.fl_str_mv | Archivos de cardiología de México. 2021;91:47-54 |
| dc.rights.license.none.fl_str_mv | Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0) |
| dc.rights.none.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.source.none.fl_str_mv | reponame:COLIBRI instname:Universidad de la República instacron:Universidad de la República |
| dc.subject.es.fl_str_mv | COVID-19 Tromboprofilaxia Trombosis Tromboembolia SARS-CoV-2 Neumonía |
| dc.subject.other.es.fl_str_mv | ANTICOAGULANTES USOS TERAPÉUTICOS CONSENSO HUMANOS PREVENCIÓN DE ENFERMEDADES TROMBOEMBOLIA VENOSA TERAPÉUTICA |
| dc.title.none.fl_str_mv | Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT) |
| dc.type.es.fl_str_mv | Artículo |
| dc.type.none.fl_str_mv | info:eu-repo/semantics/article |
| dc.type.version.none.fl_str_mv | info:eu-repo/semantics/publishedVersion |
| description | Cecilia Guillermo-Esposito 1, Patricia Casais 2, Gabriela Cesarman-Maus 3, Fernanda Andrade-Orsi 4, Rosario Martínez-Rovira 5, Joao C de-Campos-Guerra 6, Suely M Rezende 7, Raúl Izaguirre-Ávila 8, Raúl Altman 9, José Ceresetto 9, Cecilia Colorio 9, Cristina Duboscq 9, Claudio Martín Rosa 9, Soledad Molnar 9, Diana García 9, Mario Luis Tejarina 10, Nelson Nina García 10, Juan Choque Pacheco 10, Chiara Chindamo J. María 11, Gloria Ramos Ramos 12, Guillermo León Basantes 12, Aura Milena Reyna 12, Miriam Cantero Guevara 12, Mateo Porres Aguilar 13, Luis Meillón 13, Flavio Adrián Grimaldo 13, Ludwing Alexander Bacon Fonseca 14, Al Ávila Milord 15, Ricardo Aguilar 15, Rafael Aparicio 15, Paula de Guggiari 16, Gloria Chumpitaz 17, Pedro Pablo García 17, Blanca Steffano 18, Sandra Damiano 18, Juan Serrano 19, Marisol Zavahra 19 |
| eu_rights_str_mv | openAccess |
| format | article |
| id | COLIBRI_7c6ced5dc2f6d9864e03c7bf8677107d |
| identifier_str_mv | Guillermo Espósito C, Casais P, Cesarman-Maus G y otros. Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT). Archivos de cardiología de México [en línea]. 2021;91:47-54 10.24875/ACM.20000291 1665-1731 |
| instacron_str | Universidad de la República |
| institution | Universidad de la República |
| instname_str | Universidad de la República |
| language | eng |
| language_invalid_str_mv | en |
| network_acronym_str | COLIBRI |
| network_name_str | COLIBRI |
| oai_identifier_str | oai:colibri.udelar.edu.uy:20.500.12008/55391 |
| publishDate | 2021 |
| reponame_str | COLIBRI |
| repository.mail.fl_str_mv | karina.camps@seciu.edu.uy |
| repository.name.fl_str_mv | COLIBRI - Universidad de la República |
| repository_id_str | 4771 |
| rights_invalid_str_mv | Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0) |
| spelling | Guillermo Espósito Cecilia, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de Clínicas. Cátedra de HematologíaCasais Patricia, Universidad de Buenos Aires (Argentina). Instituto de Investigaciones en Salud Pública. Departamento de Epidemiología Clínica y EvidenciaCesarman-Maus Gabriela, Instituto Nacional de Cancerología (México). Departamento de HematologíaAndrade-Orsi Fernanda, Universidades Estadual de Campinas (Brasil). Faculdade de Ciências Médicas. Departamento de PatologiaMartínez-Rovira Raúl, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de Clínicas. Unidad de Hemostasis y Trombosisde-Campos-Guerra Joao C., Centro de Hematologia de São Paulo (Brasil). Hospital Israelita Albert EinsteinRezende Suely M., Universidade Federal de Minas Gerais (Brasil). Faculdade de MedicinaIzaguirre-Ávila Raúl, Instituto Nacional de Cardiología Ignacio Chávez (México). Departamento de HematologíaAMÉRICA LATINA2026-06-05T14:25:33Z2026-06-05T14:25:33Z2021Guillermo Espósito C, Casais P, Cesarman-Maus G y otros. Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT). Archivos de cardiología de México [en línea]. 2021;91:47-54https://hdl.handle.net/20.500.12008/5539110.24875/ACM.200002911665-1731Cecilia Guillermo-Esposito 1, Patricia Casais 2, Gabriela Cesarman-Maus 3, Fernanda Andrade-Orsi 4, Rosario Martínez-Rovira 5, Joao C de-Campos-Guerra 6, Suely M Rezende 7, Raúl Izaguirre-Ávila 8, Raúl Altman 9, José Ceresetto 9, Cecilia Colorio 9, Cristina Duboscq 9, Claudio Martín Rosa 9, Soledad Molnar 9, Diana García 9, Mario Luis Tejarina 10, Nelson Nina García 10, Juan Choque Pacheco 10, Chiara Chindamo J. María 11, Gloria Ramos Ramos 12, Guillermo León Basantes 12, Aura Milena Reyna 12, Miriam Cantero Guevara 12, Mateo Porres Aguilar 13, Luis Meillón 13, Flavio Adrián Grimaldo 13, Ludwing Alexander Bacon Fonseca 14, Al Ávila Milord 15, Ricardo Aguilar 15, Rafael Aparicio 15, Paula de Guggiari 16, Gloria Chumpitaz 17, Pedro Pablo García 17, Blanca Steffano 18, Sandra Damiano 18, Juan Serrano 19, Marisol Zavahra 19Affiliations 1Cátedra de Hematología, Facultad de Medicina, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay. 2Departamento de Epidemiología Clínica y Evidencia, Instituto de Investigaciones en Salud Pública, Universidad de Buenos Aires, Argentina. 3Departamento de Hematología, Instituto Nacional de Cancerología, Ciudad de México, México. 4Departamento de Patología Clínica, Escuela de Ciencias Médicas, Universidad de Campinas, Campinas-Sao Paulo, Brasil. 5Unidad de Hemostasis y Trombosis, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay. 6Hospital Israelita Albert Einstein, Centro de Hematología de Sao Paulo, Sao Paulo, Brasil. 7Facultad de Medicina, Universidad Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brasil. 8Departamento de Hematología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México. 9Argentina 10Bolivia 11Brasil 12Colombia 13México 14Nicaragua 15Panamá 16Paraguay 17Perú 18Uruguay 19VenezuelaCoagulopathy and thrombosis associated with coronavirus disease 2019 (COVID-19) represent a major issue in the management of this disease. In the past months, clinical studies have demonstrated that COVID-19 patients present with a particular hypercoagulable state, in which a markedly increased D-dimer concomitant with increased levels of fibrinogen are observed. This hypercoagulable state leads to an increased risk of thrombosis, which seems to be higher among those patients with critical symptoms of COVID-19. The best therapeutic approach to prevent thrombotic events in COVID-19 has not been determined yet and several questions regarding thromboprophylaxis therapy, such as the time to initiate anticoagulation, type of anticoagulant and dose regimen, have emerged among physicians. To address these concerns, several medical societies have published position papers to provide the opinion of thrombosis experts on the management of coagulopathy and thrombosis associated with COVID-19. In line with this, the Latin America Cooperative Group of Hemostasis and Thrombosis (Grupo CLAHT) has constituted a panel of experts in thrombosis and hemostasis to discuss the available data on this topic. The aim of this review is to summarize the current evidence regarding hemostatic impairment and thrombotic risk in COVID-19 and to provide a carefully revised opinion of Latin American experts on the thromboprophylaxis and management of thrombotic events and coagulopathy in patients with suspected COVID-19.Submitted by Almiñana María Cecilia (marialminana@gmail.com) on 2026-06-04T13:50:43Z No. of bitstreams: 2 license_rdf: 27293 bytes, checksum: d62648cf14c1e37917d392ac87012955 (MD5) Guidelines for prophylaxis and anti thrombotic treatment.pdf: 3743754 bytes, checksum: b5dcdb3550e165da4b424d36d0dc0a84 (MD5)Approved for entry into archive by Almiñana María Cecilia (marialminana@gmail.com) on 2026-06-04T16:55:58Z (GMT) No. of bitstreams: 2 license_rdf: 27293 bytes, checksum: d62648cf14c1e37917d392ac87012955 (MD5) Guidelines for prophylaxis and anti thrombotic treatment.pdf: 3743754 bytes, checksum: b5dcdb3550e165da4b424d36d0dc0a84 (MD5)Made available in DSpace by Luna Fabiana (fabiana.luna@seciu.edu.uy) on 2026-06-05T14:25:33Z (GMT). No. of bitstreams: 2 license_rdf: 27293 bytes, checksum: d62648cf14c1e37917d392ac87012955 (MD5) Guidelines for prophylaxis and anti thrombotic treatment.pdf: 3743754 bytes, checksum: b5dcdb3550e165da4b424d36d0dc0a84 (MD5) Previous issue date: 20218 p.application/pdfenengInstituto Nacional de Cardiología Ignacio ChávezArchivos de cardiología de México. 2021;91:47-54Las obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad de la República.(Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014)info:eu-repo/semantics/openAccessLicencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0)COVID-19TromboprofilaxiaTrombosisTromboemboliaSARS-CoV-2NeumoníaANTICOAGULANTESUSOS TERAPÉUTICOSCONSENSOHUMANOSPREVENCIÓN DE ENFERMEDADESTROMBOEMBOLIA VENOSATERAPÉUTICAGuidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT)Artículoinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:COLIBRIinstname:Universidad de la Repúblicainstacron:Universidad de la RepúblicaGuillermo Espósito, CeciliaCasais, PatriciaCesarman-Maus, GabrielaAndrade-Orsi, FernandaMartínez-Rovira, Raúlde-Campos-Guerra, Joao C.Rezende, Suely M.Izaguirre-Ávila, RaúlLICENSElicense.txtlicense.txttext/plain; charset=utf-84267http://localhost:8080/xmlui/bitstream/20.500.12008/55391/5/license.txt6429389a7df7277b72b7924fdc7d47a9MD55CC-LICENSElicense_urllicense_urltext/plain; charset=utf-850http://localhost:8080/xmlui/bitstream/20.500.12008/55391/2/license_urla006180e3f5b2ad0b88185d14284c0e0MD52license_textlicense_texttext/html; charset=utf-835935http://localhost:8080/xmlui/bitstream/20.500.12008/55391/3/license_text00c6a163e62314ee9d2a181a90bf9e84MD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-827293http://localhost:8080/xmlui/bitstream/20.500.12008/55391/4/license_rdfd62648cf14c1e37917d392ac87012955MD54ORIGINALGuidelines for prophylaxis and anti thrombotic treatment.pdfGuidelines for prophylaxis and anti thrombotic treatment.pdfapplication/pdf3743754http://localhost:8080/xmlui/bitstream/20.500.12008/55391/1/Guidelines+for+prophylaxis+and+anti+thrombotic+treatment.pdfb5dcdb3550e165da4b424d36d0dc0a84MD5120.500.12008/553912026-06-05 11:25:33.57oai:colibri.udelar.edu.uy:20.500.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Institucionalhttps://www.colibri.udelar.edu.uyUniversidadhttps://udelar.edu.uy/https://www.colibri.udelar.edu.uy/oai/requestkarina.camps@seciu.edu.uyUruguayopendoar:47712026-06-05T14:25:33COLIBRI - Universidad de la Repúblicafalse |
| spellingShingle | Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT) Guillermo Espósito, Cecilia COVID-19 Tromboprofilaxia Trombosis Tromboembolia SARS-CoV-2 Neumonía ANTICOAGULANTES USOS TERAPÉUTICOS CONSENSO HUMANOS PREVENCIÓN DE ENFERMEDADES TROMBOEMBOLIA VENOSA TERAPÉUTICA |
| status_str | publishedVersion |
| title | Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT) |
| title_full | Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT) |
| title_fullStr | Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT) |
| title_full_unstemmed | Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT) |
| title_short | Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT) |
| title_sort | Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT) |
| topic | COVID-19 Tromboprofilaxia Trombosis Tromboembolia SARS-CoV-2 Neumonía ANTICOAGULANTES USOS TERAPÉUTICOS CONSENSO HUMANOS PREVENCIÓN DE ENFERMEDADES TROMBOEMBOLIA VENOSA TERAPÉUTICA |
| url | https://hdl.handle.net/20.500.12008/55391 |
